3 Ways Ariad Pharmaceuticals Can Salvage Iclusig

Iclusig has taken quite a few knocks since October, but there are three ways Ariad could rebuild the brand's value and boost shareholder value in the process.

Feb 11, 2014 at 1:45PM

If you'd like to quickly understand the promises and perils of the biotechnology sector, have a quick look at Ariad Pharmaceuticals' (NASDAQ:ARIA) chart over the past six months, which features a nauseating 90% drop and a roughly 300% pop since its lows.

Ariad Pharmaceuticals has taken investors for a wild ride thanks to a two-year follow-up study, released in October, on its only FDA-approved therapy, Iclusig. The drug, which is approved to treat Philadelphia chromosome-positive acute lymphoblastic leukemia, or Ph+-ALL, was shown to increase the chance of serious vaso-occlusive events (i.e., blood clots) at the 24-month mark compared to its prior adverse events readings at the 11-month mark.

This potentially serious toxicity issue caused a spiraling of negative events, including the discontinuation of the Epic trial in October which would have expanded Iclusig's usage to treatment-naïve chronic myeloid leukemia patients (drastically broadening the scope of Iclusig's application), and also led to the temporary sales ban of Iclusig in the U.S.

Fast-forwarding a bit, Iclusig has returned to U.S. pharmacy shelves with a more expansive warning label. It will remain on the market in Europe as well with the expectation that doctors will closely monitor the cardiovascular health of patients receiving the medication.

In the U.S., Iclusig is viewed as something of a last-resort treatment for Ph+-ALL. Yet Ariad CEO Harvey Berger indicated in a presentation last month at the JPMorgan Healthcare Conference that Iclusig is statistically the most effective therapy available in chronic myeloid leukemia patients who have tried and failed two lines of tyrosine kinase inhibitors.

G
Source: Ariad Pharmaceuticals, Lipton et al, ASH 2013.

As Berger pointed out, the percentage of patients who achieved a complete cytogenic response was close to 60% with Iclusig, while Pfizer's Bosulif and Novartis' Tasigna delivered complete cytogenic response rates closer to 30%.

In other words, the therapy appears to work, but its toxicity is still a concern; so how does the company approach this to maximize shareholder value and Iclusig's long-term potential?

I believe the company has three options, though the likelihood of some pathways is clearly better than others.

Pathway No. 1: Seek a partner
No biotech company shares revenue if it doesn't have to -- it's a knock on its pride and pocketbook -- but I see no better way for Ariad to rebuild the brand value of Iclusig than through a partnership.

Ariad would be smart to look at ways of licensing the marketing rights of Iclusig in Europe and the rest of the world. The reasoning is that U.S. insurers tend to be pretty straightforward about what they will and won't cover. That's not always the case in Europe, where each country handles marketing and pricing on a step-by-step basis. Ariad understands the U.S. market well because it operates here, but it could certainly use a company with better overseas marketing knowledge.

Two possibilities here are cancer-focused European juggernaut Roche (NASDAQOTH:RHHBY) or Merck's (NYSE:MRK) rest of world operations, known as MSD outside of North America.

Roche makes sense for obvious reasons. The company has a few dozen ongoing cancer trials, it's based in Europe, and it has a mammoth marketing force and countless relationships with physicians. What's more, though the two companies dance around many of the same treatment aspects, neither would be stepping on the other's toes through direct competition -- Roche's focus is on chronic lymphocytic leukemia, while Ariad's Iclusig targets select types of chronic myeloid leukemia.

MSD would be an interesting fit only because Ariad and Merck (in the U.S.) have partnered up once previously in the development of sarcoma drug ridaforolimus, which extended progression-free survival by three weeks but couldn't get a nod of approval from either the FDA or the European Medicines Agency. Their failure on that project does not mean the companies could not resume a working relationship.

This pathway, though, might be a tough sell as Berger has made it pretty clear he'd like Ariad to go it alone. In an interview with PharmExec in August, before the Iclusig follow-up data was available, Berger addressed why his company hadn't sought a partner,

It's the foundation of why we think we're a sustainable, long-term, successful global oncology business. It goes back to two corporate values we have: scientific excellence, and clinical scholarship. The second one, clinical scholarship, we view as a critical part of our core values, and as a key distinguishing feature.

In other words, he believes licensing out drugs to companies that won't know how to use those drugs isn't the best practice for the future of the biotech industry. This makes a partnership here possible, but perhaps difficult for Ariad's upper management to swallow.

Pathway No. 2: Test combination therapies
Iclusig is now brandishing a bruised reputation thanks to its beefed up warning label, and it's unlikely that sales will pick up dramatically, or that its indications will expand meaningfully, unless its toxicity can be reduced. This leads to the next possible pathway to rebuilding Iclusig: testing a number of combination therapies.

G

Source: Ariad Pharmaceuticals.

Berger said at the JPMorgan Healthcare Conference that Ariad plans to test different dosing options of Iclusig in the second half of the year to determine if lower dosing can be just as effective as current dosing options. If so, then the potential for serious adverse events should drop.

Berger also announced the potential for Iclusig to be combined with an anti-coagulant therapy in a study later this year. This idea has me intrigued as it would, on paper at least, reduce the risk of thrombosis. However, drug-to-drug interactions can be far different on paper than how they actually behave in the human body.

The point being that Ariad has dosing and combination therapy options. The question is whether Ariad will step up and spend the money to conduct these studies. I believe, based on the market potential for Iclusig if its toxicity were even halved, that it is in Ariad's best interests to spend heavily on these combo drug studies to see if there is a pharmacologic solution to its toxicity issue.

Pathway No. 3: Seek a full or partial buyout
Lastly, Ariad's management could always throw up the white flag and put a for-sale sign out on its front lawn (for the drug or the entire company) if marketing Iclusig proves too taxing, or if it finds little luck in combining Iclusig with other therapies.

I personally consider this pathway to be the least likely, but it's not 100% out of the question, either.

From a buyer's standpoint, Iclusig has limited current market potential and serious side-effect precursors that will keep it in a "last-in-line" position in its only approved indication for the near future. This is going to keep most offers for the company relative low -- if there are any buyout offers in the first place.

Ariad Employee

Source: Ariad Pharmaceuticals.

Then again, Ariad does offer some tangible and intangible benefits, such as highly valuable carryover tax-loss benefits and $218 million in net cash. Furthermore, though toxicity again may limit its marketability, early results from a gastrointestinal stromal tumor study confirmed the positive effects of Iclusig on previously unresponsive tumors. This means the potential for new indications isn't out of the question.

Given these pluses and minuses, Ariad could sell the rights to Iclusig in order to build up cash value to be used on development of its ALK-positive non-small cell lung cancer drug API26113, as well as start new research and development projects, or it can look to sell the entire company and dangle its tax-loss benefits as the carrot to draw in a prospective bidder.

Reporting last month from the London Daily Mail had pegged Eli Lilly as a prospective buyer given the company's struggling pipeline -- about three-quarters of Lilly's pipeline will come off patent in the 2010-2017 range -- but I've pretty much thrown that rumor into the ridiculous pile.

A more suitable buyer would be a cash-rich pharmaceutical company that also fully understands blood-borne cancers. If there is to be an Ariad buyout -- which I'd remind you I find very unlikely -- I would point my finger toward Celgene (NASDAQ:CELG) as the most likely candidate. Celgene targets a number of leukemia types with blockbuster Revlimid, and it could certainly benefit from the tax-loss carryover from Ariad, as well as Iclusig's third-line sales potential in Ph+-ALL and a CML indication further down the road.

A long road
Ariad remains a work in progress, but it does have options to improve shareholder value and rebuild the Iclusig brand. Will Ariad be successful if it embarks on any of these pathways? That's a question that only time will answer.

Ariad may be up nearly 300% from its lows, but even it's going to be hard-pressed to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers